Discover undervalued stocks with Eulerpool.

Subscribe for $2

Vertex Pharmaceuticals Stock VRTX

Price

0
Today +/-
-0
Today %
-0 %

Vertex Pharmaceuticals stock price

Loading chart...
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Vertex Pharmaceuticals stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Vertex Pharmaceuticals stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Vertex Pharmaceuticals stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Vertex Pharmaceuticals's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Vertex Pharmaceuticals Stock Price History

DateVertex Pharmaceuticals Price
9/19/20250 undefined
9/19/2025383.13 undefined
9/18/2025387.12 undefined
9/17/2025387.16 undefined
9/16/2025392.33 undefined
9/15/2025393.22 undefined
9/12/2025389.01 undefined
9/11/2025397.38 undefined
9/10/2025388.56 undefined
9/9/2025395.17 undefined
9/8/2025395.26 undefined
9/5/2025396.13 undefined
9/4/2025396.20 undefined
9/3/2025393.58 undefined
9/2/2025401.01 undefined
8/29/2025391.03 undefined
8/28/2025392.06 undefined
8/27/2025389.09 undefined
8/26/2025385.86 undefined
8/25/2025388.95 undefined
8/22/2025395.68 undefined
8/22/2025395.13 undefined
8/21/2025397.47 undefined

Vertex Pharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Vertex Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Vertex Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Vertex Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Vertex Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Vertex Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Vertex Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Vertex Pharmaceuticals’s growth potential.

Vertex Pharmaceuticals Revenue, EBIT and net profit per share

DateVertex Pharmaceuticals RevenueVertex Pharmaceuticals EBITVertex Pharmaceuticals Net Income
2030e19.79 B undefined0 undefined8 B undefined
2029e17.9 B undefined8.43 B undefined7.41 B undefined
2028e16.11 B undefined7.47 B undefined6.5 B undefined
2027e14.58 B undefined6.96 B undefined5.93 B undefined
2026e13.39 B undefined6.33 B undefined5.4 B undefined
2025e12.22 B undefined5.4 B undefined4.75 B undefined
202411.02 B undefined4.4 B undefined-535.6 M undefined
20239.87 B undefined4.36 B undefined3.62 B undefined
20228.93 B undefined4.44 B undefined3.32 B undefined
20217.57 B undefined2.78 B undefined2.34 B undefined
20206.21 B undefined2.86 B undefined2.71 B undefined
20194.16 B undefined1.2 B undefined1.18 B undefined
20183.05 B undefined663.97 M undefined2.1 B undefined
20172.49 B undefined392.83 M undefined263.19 M undefined
20161.7 B undefined11.2 M undefined-112.05 M undefined
20151.03 B undefined-464.67 M undefined-556.33 M undefined
2014580.42 M undefined-641.49 M undefined-738.56 M undefined
20131.21 B undefined-156.59 M undefined-445.03 M undefined
20121.53 B undefined48.57 M undefined-107.35 M undefined
20111.41 B undefined221.69 M undefined29.28 M undefined
2010143.37 M undefined-694.58 M undefined-754.63 M undefined
2009101.89 M undefined-592.78 M undefined-642.18 M undefined
2008175.5 M undefined-458.38 M undefined-459.85 M undefined
2007199.01 M undefined-412.67 M undefined-391.28 M undefined
2006216.36 M undefined-225.39 M undefined-206.89 M undefined
2005160.89 M undefined-141.74 M undefined-203.42 M undefined

Vertex Pharmaceuticals Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)
REVENUE GROWTH (%)
GROSS MARGIN (%)
GROSS INCOME (B)
NET INCOME (B)
NET INCOME GROWTH (%)
SHARES (M)
DOCUMENTS
199019911992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025e2026e2027e2028e2029e2030e
000.010.030.020.030.020.050.060.110.150.090.090.070.10.160.220.20.180.10.141.411.531.210.581.031.72.493.054.166.217.578.939.8711.0212.2213.3914.5816.1117.919.79
-100.0025.00480.00-20.6917.39-33.33172.2226.5374.1941.67-44.4410.59-26.6047.8356.8635.00-7.87-12.06-42.2941.58886.018.30-20.69-52.1177.9364.9246.1822.4736.5949.0922.0617.9010.5211.6610.909.578.8510.5111.1110.58
474,450.00237,225.00189,780.0032,720.6941,256.5235,144.4488.8979.5956.4571.3071.9011,163.5310,094.6813,752.179,302.945,930.634,393.064,768.345,422.29100.00100.0095.5384.4892.7393.1088.6687.8489.0386.5886.8688.1488.0687.9187.2186.1177.6570.8665.1058.9153.0247.95
0000000.020.040.040.080.11000000000.10.141.351.291.120.540.921.52.222.643.625.476.677.858.619.49000000
-0-0.01-0.010-0.02-0.02-0.04-0.02-0.05-0.04-0.03-0.07-0.11-0.2-0.17-0.2-0.21-0.39-0.46-0.64-0.750.03-0.11-0.45-0.74-0.56-0.110.262.11.182.712.343.323.62-0.544.755.45.936.57.418
-25.0060.00-125.00-950.0023.53104.76-55.81168.42-19.61-17.0794.1263.6481.48-15.3122.291.4889.8117.3939.8717.45-103.85-468.97315.8965.84-24.66-79.86-334.82696.96-43.89130.53-13.6141.848.94-114.78-988.6013.599.879.5614.007.98
13.3516.1924.2224.931.6434.4639.2255.2361.7462.667.6874.4675.757778.5789.24113.22128.99140.56173.26200.4208.81215.26224.91235.31241.31244.69253.23259.19260.7263.4259.9259.1260.5257.9000000
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Details

Keystats

ⓘ

Revenue and Growth

The Vertex Pharmaceuticals Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Vertex Pharmaceuticals is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETS
CASH BALANCE (B)
RECEIVABLES (B)
OTHER REC. (M)
INVENTORIES (B)
OTHER CURRENT LIAB. (M)
CURRENT ASSETS (B)
TANGIBLE ASSETS (B)
LONG-T. INVEST. (B)
LONG-T. REC. (M)
INTANGIBLE ASSETS (M)
GOODWILL (B)
OTHER NON-CURRENT ASSETS (B)
NON-CURRENT ASSETS (B)
TOTAL ASSETS (B)
LIABILITIES
COMMON STOCK (M)
ADDITIONAL PAID-IN CAPITAL (B)
RETAINED EARNINGS (B)
OTHER EQUITY (M)
UNREAL. GAINS/LOSSES (M)
EQUITY (B)
LIABILITIES (M)
PROVISIONS (B)
OTHER SHORT-TERM LIAB. (M)
SHORT-TERM DEBTS (M)
LONG-TERM DEBT PORTION (M)
SHORT-TERM REC. (B)
LONG-T. LIAB. (M)
DEFERRED TAXES (M)
OTHER LIAB. (B)
LONG-T. LIABILITIES (B)
DEBT (B)
TOTAL CAPITAL (B)
19901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024
                                                                     
00.050.040.050.110.090.140.330.270.150.810.740.630.580.390.360.70.460.831.281.030.971.321.471.391.041.432.093.173.816.667.5210.7811.226.12
000000000.010.010.030.020.010.010.010.020.060.030.020.010.010.180.140.090.080.180.20.280.410.630.891.141.441.561.61
000000000000000000000000003.2128.915.18000000
0000000000000000000000.110.030.010.030.060.080.110.120.170.280.350.460.741.21
0.160.170.2510.410.962.193.283.384.569.4612.638.393.322.53.33.864.6611.9912.5113.166.7794.6623.8452.59129.85115.08138.22135.64213.52308.35545.8553.5623.7665.7
00.050.040.050.110.090.150.340.280.170.860.780.660.590.40.390.770.50.871.311.061.331.591.591.551.411.832.653.844.828.139.5613.2314.149.6
000.010.010.010.010.010.020.030.040.040.080.10.080.060.050.060.070.070.060.070.130.430.70.720.70.70.790.810.831.281.421.461.452.58
0000000000.070.010.030.030.020.020.070.060.01000000000.020.02000.020.090.12.65.17
000000000000000000000000030000000000
0000000000000000000518.7518.7663.5663.5029284.34284.34290400400400603.6898.8888.5
00000000000000000000.030.030.030.030.030.040.050.050.050.051111.091.091.09
00000000.010.010.020.030.040.040.030.060.040.030.030.040.040.050.050.04000.030.010.011.541.260.910.961.672.553.2
00.010.010.010.010.010.010.020.040.130.080.150.160.130.140.160.150.10.110.650.670.871.170.730.791.091.070.92.43.53.623.874.928.5912.94
0.010.060.050.060.120.10.160.360.320.30.940.930.820.720.550.550.920.60.981.961.732.22.762.322.332.52.93.556.258.3211.7513.4318.1522.7322.53
                                                                     
0.070.120.1200.170.170.210.270.270.530.740.750.760.780.811.081.241.311.491.982.022.072.152.322.392.432.452.512.552.592.62.52.62.62.6
0.010.060.060.070.140.140.250.450.460.460.760.780.790.810.831.241.71.862.283.783.954.24.525.325.786.26.517.167.427.947.896.887.397.456.67
-0.01-0.01-0.02-0.02-0.04-0.06-0.1-0.12-0.17-0.21-0.25-0.31-0.42-0.62-0.79-0.99-1.2-1.59-2.05-2.69-3.44-3.41-3.52-3.97-4.71-5.26-5.37-5.12-2.99-1.850.863.26.5210.149.61
0000-0.20-0.31-2.92-1.75-1.964.0511.116.761.58-13.03-16.28-0.960.883.17-0.64-1.07-1.05-0.75-0.351.041.823.65-36.051.2-2.48-68.8116.40.9-23.9120.7
00000000000000000000000.20.04-0.12017.5224.48-0.540.50.33-0.5-0.19.67.1
0.010.050.040.050.110.090.150.330.280.250.510.480.380.190.040.240.510.270.241.10.50.7911.361.080.941.162.034.446.098.6910.113.9117.5816.41
0.340.760.6831.43.021.695.366.036.858.4411.6316.7512.316.666.2115.3732.7551.7636.9935.8574.64101.2949.3371.1974.9461.4573.99110.9987.61155.14195303.9364.9413
00000000.010.010.010.030.040.030.10.090.060.10.10.110.130.140.260.270.270.240.310.310.450.61.061.311.52.052.592.71
0.250.270.2910.640.20.253.112.8312.6628.3339.511.897.7547.7431.4533.8925.5337.6874.96152.4260.850.1757.3922.2730.6797.25264.6394.99160.8368.64399.5345.4543431.8
0000000000000000000000000030000000000
0.841.181.8321.662.083.263.664.784.865.074.582.218.664.692.99103.7637.0521.2647.3143.14013.7116.8932.0186.8419.4322.539.8230.2942.4346.940.850.65.2
0000.010.010.010.010.020.020.040.070.090.060.140.150.10.250.20.220.280.470.390.430.40.370.510.790.811.121.331.882.142.743.553.56
2.42.143.3444.734.916.739.3311.829.04357.27323.03325.94340.73337.92180.1200287.5121.77400400683.2489.69792.94739.4521.34583.9581.55538.58539.04509.8430.8376.1112.8
0000000000000000000160.28160.28243.71280.37015.04110.44134.066.340000000
000000000000.040.050.050.020.030.140.130.240.290.190.20.130.080.060.050.110.110.110.360.650.681.071.232.45
0000000.010.010.010.010.360.360.370.390.360.210.160.130.530.570.750.851.090.560.870.90.770.70.690.91.191.191.51.62.56
000.010.010.010.010.020.030.030.050.430.450.440.530.510.310.420.330.740.861.221.241.520.961.241.41.561.51.812.233.063.334.245.156.12
0.010.060.050.060.120.10.160.360.320.30.940.930.820.720.550.550.920.60.981.961.732.032.522.322.312.342.723.536.258.3211.7513.4318.1522.7322.53
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Vertex Pharmaceuticals provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Vertex Pharmaceuticals's financial health and stability.

Assets

Vertex Pharmaceuticals's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Vertex Pharmaceuticals must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Vertex Pharmaceuticals after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Vertex Pharmaceuticals's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (B)
DEPRECIATION (M)
DEFERRED TAXES (M)
CHANGES IN WORKING CAPITAL (M)
NON-CASH ITEM (B)
PAID INTEREST (M)
PAID TAXES (B)
NET CASH FLOW FROM OPERATING ACTIVITIES (B)
CAPITAL EXPENDITURES (M)
CASH FLOW FROM INVESTING ACTIVITIES (M)
CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)
INTEREST INCOME AND EXPENSES (M)
NET DEBT CHANGE (M)
NET CHANGE IN EQUITY (M)
CASH FLOW FROM FINANCING ACTIVITIES (M)
CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)
TOTAL DIVIDENDS PAID (M)
NET CHANGE IN CASH FLOW (B)
FREE CASH FLOW (M)
SHARE-BASED COMPENSATION (M)
1990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
-0-0.01-0.010-0.02-0.02-0.04-0.02-0.05-0.04-0.03-0.07-0.11-0.2-0.17-0.2-0.21-0.39-0.46-0.64-0.750.04-0.05-0.69-0.74-0.59-0.080.092.091.182.712.343.323.62
112333346912172423292725273230303538486362616172106109125148181
0000000000000000000-20-736-2850317-120-1,512167277-154-275-536
000201-47-192381670-12-521234713861-63-192-11-5-71-86-512238-66-54-105340-265
00000000000.010-0.01-0.060.010.060.040.060.120.220.240.390.371.010.350.470.491.090.710.540.640.881.091.12
000000001120181615151673610013131169858368665554565243
00000000000000000000000.01000-00.010.010.020.190.481.061.68
-0-0-0.010.01-0.01-0.02-0.04-0.01-0.05-0.02-0.01-0.01-0.08-0.17-0.14-0.17-0.02-0.25-0.23-0.43-0.640.140.27-0.05-0.57-0.370.240.841.271.573.252.644.133.54
-1-1-1-4-4-3-4-8-10-18-18-49-38-17-12-17-32-32-32-23-38-34-71-51-51-45-56-259-95-75-259-235-204-258
0-25-93-16-29-50-139-1824-307-145-16119107-1-208405-360-5087212-425-548226851-483-202-1,23599-340-321-3,141
0-24-88-12-25-46-131-742-289-952213611915-176437-328-48545247-354-2133314107-223-106-1,159359-105-116-2,883
0000000000000000000000000000000000
0-1-1-2-1-1-1-201499-23125-1200-42258149391-155-21-832723-6-284-12-29-29-24-85-43
5510373185202371191813128197366323628493312419126527418568344-60151-274-1,323186-293
550-1474110520139619-51337-8197365-10620999425-12417218054918813368-71126-505-1,478-67-562
000222211000000-4000000-942-12071824-202-130-168-226
0000000000000000000000000000000000
00.02-0.020.020.04-0.040.010.06-0.060.010.3-0.16-0.08-0.01-0.040.020.140.140.030.06-0.20.230.010.080.060.090.420.440.990.462.870.813.71-0.14
-4.1-3.7-6.83.9-18.9-19.1-48.3-15.1-56.4-38.3-30.7-56.4-118.4-185-154.6-189.1-54.9-284.9-258.7-451.1-673.5109.1196.7-103-624.3-410.7179.5585.51,174.81,493.82,993.72,408.53,925.23,278.9
0000000000000000000000000000000000

Vertex Pharmaceuticals stock margins

The Vertex Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Vertex Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Vertex Pharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Vertex Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the Vertex Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Vertex Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Vertex Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Vertex Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Vertex Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Vertex Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Vertex Pharmaceuticals Margin History

Vertex Pharmaceuticals Gross marginVertex Pharmaceuticals Profit marginVertex Pharmaceuticals EBIT marginVertex Pharmaceuticals Profit margin
2030e86.11 %0 %40.43 %
2029e86.11 %47.09 %41.41 %
2028e86.11 %46.37 %40.36 %
2027e86.11 %47.74 %40.71 %
2026e86.11 %47.25 %40.33 %
2025e86.11 %44.16 %38.9 %
202486.11 %39.89 %-4.86 %
202387.21 %44.17 %36.68 %
202287.9 %49.67 %37.2 %
202188.06 %36.73 %30.92 %
202088.14 %46.03 %43.7 %
201986.84 %28.77 %28.27 %
201886.56 %21.79 %68.79 %
201789.04 %15.78 %10.58 %
201687.85 %0.66 %-6.58 %
201588.65 %-45.01 %-53.89 %
201493.16 %-110.52 %-127.25 %
201392.66 %-12.92 %-36.72 %
201284.5 %3.18 %-7.03 %
201195.49 %15.72 %2.08 %
2010100 %-484.46 %-526.35 %
2009100 %-581.79 %-630.27 %
200886.11 %-261.18 %-262.02 %
200786.11 %-207.36 %-196.61 %
200686.11 %-104.17 %-95.63 %
200586.11 %-88.1 %-126.43 %

Vertex Pharmaceuticals Stock Sales Revenue, EBIT, Earnings per Share

The Vertex Pharmaceuticals earnings per share therefore indicates how much revenue Vertex Pharmaceuticals has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Vertex Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Vertex Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Vertex Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Vertex Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Vertex Pharmaceuticals Revenue, EBIT and net profit per share

DateVertex Pharmaceuticals Sales per ShareVertex Pharmaceuticals EBIT per shareVertex Pharmaceuticals Earnings per Share
2030e76.74 undefined0 undefined31.02 undefined
2029e69.4 undefined0 undefined28.74 undefined
2028e62.46 undefined0 undefined25.21 undefined
2027e56.52 undefined0 undefined23.01 undefined
2026e51.92 undefined0 undefined20.94 undefined
2025e47.39 undefined0 undefined18.43 undefined
202442.73 undefined17.04 undefined-2.08 undefined
202337.89 undefined16.73 undefined13.89 undefined
202234.47 undefined17.12 undefined12.82 undefined
202129.14 undefined10.7 undefined9.01 undefined
202023.56 undefined10.84 undefined10.29 undefined
201915.97 undefined4.59 undefined4.51 undefined
201811.76 undefined2.56 undefined8.09 undefined
20179.83 undefined1.55 undefined1.04 undefined
20166.96 undefined0.05 undefined-0.46 undefined
20154.28 undefined-1.93 undefined-2.31 undefined
20142.47 undefined-2.73 undefined-3.14 undefined
20135.39 undefined-0.7 undefined-1.98 undefined
20127.09 undefined0.23 undefined-0.5 undefined
20116.76 undefined1.06 undefined0.14 undefined
20100.72 undefined-3.47 undefined-3.77 undefined
20090.59 undefined-3.42 undefined-3.71 undefined
20081.25 undefined-3.26 undefined-3.27 undefined
20071.54 undefined-3.2 undefined-3.03 undefined
20061.91 undefined-1.99 undefined-1.83 undefined
20051.8 undefined-1.59 undefined-2.28 undefined

Vertex Pharmaceuticals business model

Vertex Pharmaceuticals Inc is a biopharmaceutical company that focuses on researching, developing, and marketing therapies for rare diseases. The company was founded in 1989 and is headquartered in Boston, Massachusetts, USA. Since its inception, Vertex has been dedicated to pushing the boundaries of science to develop groundbreaking therapies for diseases such as cystic fibrosis and other rare genetic disorders. The company's history began in 1989 when Joshua Boger, a former employee of Merck & Co., founded the company with the goal of becoming a leading developer of therapies for rare diseases. In 1993, Vertex went public, achieving significant success. In 2012, the company announced the development of the first approved therapy for the treatment of cystic fibrosis, Kalydeco. Since then, Vertex has expanded its technology and production capabilities and continues to work on developing additional therapies for rare genetic disorders. The business model of Vertex Pharmaceuticals Inc is based on researching and developing therapies for rare genetic disorders. The company collaborates closely with patients, leading scientists, and medical professionals to develop groundbreaking therapies. Vertex is a vertically integrated company, handling everything from research and development to production and marketing in-house. This allows the company to maintain control over the entire development and production process to ensure the highest quality products. Vertex is divided into different divisions to organize its activities. The Paris research facility specializes in the development of therapies for cystic fibrosis and other rare genetic disorders. The San Diego facility focuses on the development of treatments for cancer. Additionally, the company maintains research facilities in the UK and Canada. Vertex Pharmaceuticals Inc's most well-known product is Kalydeco, the first approved medication for the treatment of cystic fibrosis targeting a specific genetic mutation. Kalydeco aims to restore the function of a specific protein in the lungs, targeting the underlying cause of the disease. The company has also developed other therapies for cystic fibrosis, including Orkambi and Symdeko, which also target genetic mutations. Vertex also has therapies for cancer in its portfolio, such as the drug VX-970 currently in clinical trials for cancer treatment. In summary, Vertex Pharmaceuticals Inc is a leading biopharmaceutical company focused on developing therapies for rare genetic disorders. Since its founding in 1989, Vertex has continuously improved its technology and production capabilities, becoming one of the most innovative companies in the industry. The company is vertically integrated and consists of various research facilities dedicated to developing therapies for different diseases. Vertex has developed several groundbreaking medications for genetic disorders, including Kalydeco (the first approved medication for cystic fibrosis), Orkambi, and Symdeko. Vertex Pharmaceuticals Inc is an example of how research and development can play a significant role in treating rare diseases. Vertex Pharmaceuticals is one of the most popular companies on Eulerpool.com.

Vertex Pharmaceuticals SWOT Analysis

Strengths

Vertex Pharmaceuticals Inc has several strengths that contribute to its success in the pharmaceutical industry. Firstly, the company holds a strong portfolio of innovative and breakthrough drugs, particularly for the treatment of cystic fibrosis. These drugs have not only garnered significant market share but have also improved the quality of life for patients worldwide.

Secondly, Vertex Pharmaceuticals has established strong relationships with healthcare professionals, research institutions, and advocacy groups. These collaborations enable the company to stay at the forefront of scientific advancements and ensure the development of effective treatment options.

Lastly, the company demonstrates a robust financial position with steady revenue growth and a solid pipeline of potential drugs. This financial strength allows Vertex Pharmaceuticals to invest in research and development, ensuring continued innovation and expansion of its product offerings.

Weaknesses

Despite its strengths, Vertex Pharmaceuticals Inc also faces certain weaknesses. One major weakness is its heavy reliance on a few flagship drugs, especially those targeting cystic fibrosis. As a result, the company is exposed to market risks and regulatory uncertainties specifically associated with these drugs. Any setbacks or challenges related to these products could significantly impact the company's revenues and growth prospects.

Additionally, Vertex Pharmaceuticals operates in a highly competitive industry. Competition from other pharmaceutical companies, both established players and emerging biotech firms, poses a continuous threat to its market position. This necessitates a continual focus on innovation and differentiation to remain ahead of the competition.

Opportunities

The pharmaceutical industry offers numerous opportunities for Vertex Pharmaceuticals to further expand and solidify its position. The growing global prevalence of cystic fibrosis and other genetic disorders presents an opportunity for increased demand for the company's existing and future drugs. By strategically leveraging its expertise in disease biology, Vertex can identify new therapeutic targets and develop novel treatments for other genetic diseases.

Moreover, the increasing adoption of precision medicine and personalized therapies presents a favorable environment for Vertex Pharmaceuticals. The ability to tailor treatments to individual patients based on their genetic makeup aligns with the company's core competency in developing targeted therapies.

Threats

Despite the opportunities, Vertex Pharmaceuticals Inc faces potential threats that could impact its growth and profitability. One significant threat is the intense scrutiny and regulation of the pharmaceutical industry. Stricter regulations, pricing pressures, and reimbursement challenges can limit market access and profitability for new drugs.

Another threat comes from potential legal and intellectual property issues. Vertex operates in multiple countries, each with its own patent laws and litigation risks. Any legal disputes or challenges to its patents can lead to substantial financial losses and a loss of market exclusivity for certain drugs.

Furthermore, the current global economic landscape and geopolitical uncertainties can also impact the company's operations, including manufacturing costs, supply chain disruptions, and market demand fluctuations.

Vertex Pharmaceuticals Revenue by Segment

  • 3 years

  • 5 years

  • Max

Details
Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Vertex Pharmaceuticals Revenue by Segment

Segmente202320222021202020192018
Product revenues, net9.87 B USD8.93 B USD7.57 B USD6.2 B USD-3.02 B USD
Collaborative and royalty revenues---2.9 M USD-9.27 M USD
Other revenues--1 M USD---

  • 3 years

  • 5 years

  • Max

Details
Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Vertex Pharmaceuticals Revenue by Segment

Segmente202320222021202020192018
TRIKAFTA/KAFTRIO8.94 B USD7.69 B USD5.7 B USD3.86 B USD--
ORKAMBI326 M USD510.7 M USD771.6 M USD907.51 M USD--
KALYDECO475.5 M USD553.2 M USD684.2 M USD802.87 M USD--
SYMDEKO/SYMKEVI123 M USD180 M USD420.4 M USD628.58 M USD--
Collaborative and royalty revenues----2.1 M USD-

  • 3 years

  • 5 years

  • Max

Details
Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Vertex Pharmaceuticals Revenue by Segment

Segmente202320222021202020192018
Product revenues, net----4.16 B USD-

  • 3 years

  • 5 years

  • Max

Details
Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Vertex Pharmaceuticals Revenue by Segment

Segmente202320222021202020192018
ORKAMBI----1.33 B USD1.26 B USD
SYMDEKO/SYMKEVI----1.42 B USD768.66 M USD
KALYDECO----991.06 M USD1.01 B USD
TRIKAFTA----420.11 M USD-
Other------

Vertex Pharmaceuticals Revenue by Region

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Details
Details

Revenue by Segment

ⓘ

Overview of Revenue by Region

The chart shows revenues by region and provides a clear comparison of regional revenue distribution. Each region is clearly marked to illustrate the differences.

Interpretation and Usage

The diagram helps to identify the regions with the highest revenue and to make targeted decisions for regional expansion or investments. It supports the analysis of market potentials and strategic priorities.

Investment Strategy

An investment strategy focused on regions concentrates on the deliberate capital allocation in different markets to optimally use regional growth opportunities. It takes into account market conditions and regional risk factors.

Vertex Pharmaceuticals Revenue by Segment

DateEuropeOther CountriesOutside of the United StatesTotal revenues outside of the United StatesUnited States
20201.13 B USD249.94 M USD-1.38 B USD4.83 B USD
2019885.76 M USD214.5 M USD-1.1 B USD3.06 B USD
2018543.18 M USD139.34 M USD-682.52 M USD2.37 B USD
2017420.32 M USD81.55 M USD-501.87 M USD1.99 B USD
2016320.46 M USD59.91 M USD-380.37 M USD1.32 B USD
2015219.6 M USD49.42 M USD-269.02 M USD763.32 M USD
2014--219.34 M USD-361.07 M USD
Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Vertex Pharmaceuticals Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Vertex Pharmaceuticals historical P/E ratio, EBIT multiple, and P/S ratio

Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Vertex Pharmaceuticals shares outstanding

The number of shares was Vertex Pharmaceuticals in 2024 — This indicates how many shares 257.9 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Vertex Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Vertex Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Vertex Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Vertex Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Vertex Pharmaceuticals stock splits

In Vertex Pharmaceuticals's history, there have been no stock splits.
Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Vertex Pharmaceuticals.

Vertex Pharmaceuticals latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/20254.37 4.52  (3.45 %)2025 Q2
3/31/20254.37 4.06  (-7.2 %)2025 Q1
12/31/20244.11 3.98  (-3.07 %)2024 Q4
9/30/20244.22 4.38  (3.69 %)2024 Q3
6/30/20243 -12.83  (-527.57 %)2024 Q2
3/31/20244.14 4.76  (14.85 %)2024 Q1
12/31/20234.18 4.2  (0.36 %)2023 Q4
9/30/20234.05 4.08  (0.66 %)2023 Q3
6/30/20233.96 3.89  (-1.75 %)2023 Q2
3/31/20233.06 3.05  (-0.21 %)2023 Q1
1
2
3
4
5
...
12

Eulerpool ESG Scorecard© for the Vertex Pharmaceuticals stock

Eulerpool World ESG Rating (EESG©)

75/ 100

🌱 Environment

95

👫 Social

99

🏛️ Governance

31

Environment

Scope 1 - Direct Emissions
7,670
Scope 2 - Indirect emissions from purchased energy
14,405
Scope 3 - Indirect emissions within the value chain
474,129
Total CO₂ emissions
22,075
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees55
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Vertex Pharmaceuticals shareholders

%
Name
Stocks
Change
Date
11.14081 % Capital World Investors28,732,143198,8356/30/2025
9.25092 % The Vanguard Group, Inc.23,858,120479,2286/30/2025
6.24594 % Capital Research Global Investors16,108,2911,571,9476/30/2025
5.48767 % BlackRock Institutional Trust Company, N.A.14,152,698156,3146/30/2025
4.56581 % State Street Global Advisors (US)11,775,227-13,4306/30/2025
2.44454 % Fidelity Management & Research Company LLC6,304,462-1,317,2416/30/2025
2.38523 % Jennison Associates LLC6,151,5051,089,0636/30/2025
2.29885 % Geode Capital Management, L.L.C.5,928,747166,9876/30/2025
2.04528 % Invesco Capital Management (QQQ Trust)5,274,790-30,6977/31/2025
1.86638 % Wellington Management Company, LLP4,813,386-641,3626/30/2025
1
2
3
4
5
...
10

Vertex Pharmaceuticals Executives and Management Board

Dr. Reshma Kewalramani

(51)
Vertex Pharmaceuticals President, Chief Executive Officer, Director (since 2018)
Compensation 20.59 M

Mr. Stuart Arbuckle

(58)
Vertex Pharmaceuticals Chief Operating Officer, Executive Vice President
Compensation 9 M

Mr. Charles Wagner

(56)
Vertex Pharmaceuticals Chief Financial Officer, Executive Vice President
Compensation 7.37 M

Dr. Jeffrey Leiden

(68)
Vertex Pharmaceuticals Executive Chairman of the Board (since 2009)
Compensation 6.6 M

Dr. Ourania Tatsis

(54)
Vertex Pharmaceuticals Executive Vice President, Chief Regulatory and Quality Officer
Compensation 6.58 M
1
2
3
4

Vertex Pharmaceuticals Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Grid Dynamics Holdings A Stock
Grid Dynamics Holdings A
SupplierCustomer0,95-0,390,52-0,72-0,58-0,62
MERCK Kommanditgesellschaft auf Aktien Stock
MERCK Kommanditgesellschaft auf Aktien
SupplierCustomer0,820,740,25-0,66-0,41
TAKE Solutions Ltd. Stock
TAKE Solutions Ltd.
SupplierCustomer0,610,590,29-0,69-0,78-0,51
Certara Stock
Certara
SupplierCustomer0,580,690,34-0,69-0,78
CRISPR Therap Stock
CRISPR Therap
SupplierCustomer0,570,670,20-0,53-0,74-0,38
McKesson Corporation Stock
McKesson Corporation
SupplierCustomer0,56-0,470,600,890,940,09
Cigna Corporation Stock
Cigna Corporation
SupplierCustomer0,48-0,350,510,800,81-0,22
Merck Stock
Merck
SupplierCustomer0,470,610,45-0,59-0,27-0,49
Concert Pharmaceuticals Stock
Concert Pharmaceuticals
SupplierCustomer0,430,240,190,17-0,090,42
Royalty Pharma A Stock
Royalty Pharma A
SupplierCustomer0,370,830,840,670,350,30
1
2

Most common questions regarding Vertex Pharmaceuticals

What values and corporate philosophy does Vertex Pharmaceuticals represent?

Vertex Pharmaceuticals Inc represents values such as innovation, scientific excellence, and patient-focused approach. The company is committed to discovering transformative medicines to benefit people with serious diseases, with a particular focus on diseases such as cystic fibrosis. Vertex Pharmaceuticals Inc prioritizes research and development, leveraging cutting-edge technologies and expertise to advance their pipeline. With a culture of collaboration and a strong sense of purpose, Vertex Pharmaceuticals Inc aims to make a meaningful impact on patients' lives. By combining scientific expertise and a patient-centric approach, the company is dedicated to improving the quality of life and outcomes for those in need.

In which countries and regions is Vertex Pharmaceuticals primarily present?

Vertex Pharmaceuticals Inc is primarily present in several countries and regions. The company has a strong presence in the United States where it is headquartered, with its main facilities and operations located there. Additionally, Vertex Pharmaceuticals Inc has expanded its presence internationally. The company has a significant presence in Europe, including countries such as Germany, France, Italy, and the United Kingdom. Furthermore, Vertex Pharmaceuticals Inc has established operations in Canada and several other countries. With its global reach, Vertex Pharmaceuticals Inc aims to provide innovative pharmaceutical solutions to patients worldwide.

What significant milestones has the company Vertex Pharmaceuticals achieved?

Vertex Pharmaceuticals Inc. has achieved several significant milestones throughout its history. One of the most notable achievements is the development of breakthrough treatments for cystic fibrosis (CF). The company successfully introduced the first-ever CF medicine targeting the underlying cause of the disease, known as Kalydeco. Vertex Pharmaceuticals Inc. also made remarkable progress with other CF treatments like Orkambi, Symdeko, and Trikafta, significantly improving the lives of CF patients worldwide. Additionally, the company has expanded its pipeline with innovative therapies, focusing on various diseases including cancer, pain, and genetic disorders. These remarkable milestones highlight Vertex Pharmaceuticals Inc.'s commitment to revolutionize medical treatments and improve patient outcomes.

What is the history and background of the company Vertex Pharmaceuticals?

Vertex Pharmaceuticals Inc. is a renowned biotechnology company based in Boston, Massachusetts. Founded in 1989, Vertex has emerged as a global leader in developing innovative therapies for serious medical conditions. The company focuses on discovering transformative medicines for diseases including cystic fibrosis, pain, and other debilitating illnesses. Vertex has an esteemed track record of successful breakthroughs, with several FDA-approved drugs in its portfolio. With a strong commitment to research and development, Vertex Pharmaceuticals Inc. continues to pioneer advancements in the field of biotechnology, striving to improve the lives of countless patients worldwide.

Who are the main competitors of Vertex Pharmaceuticals in the market?

The main competitors of Vertex Pharmaceuticals Inc in the market include companies like Amgen, Gilead Sciences, and Bristol-Myers Squibb.

In which industries is Vertex Pharmaceuticals primarily active?

Vertex Pharmaceuticals Inc is primarily active in the pharmaceutical industry.

What is the business model of Vertex Pharmaceuticals?

The business model of Vertex Pharmaceuticals Inc is focused on researching, developing, and commercializing innovative therapies for serious diseases. Vertex specializes in discovering and developing small molecule drugs that target specific genetic diseases, including cystic fibrosis (CF) and other serious lung and liver diseases. The company's approach involves identifying the underlying cause of these diseases at a molecular level and developing targeted therapies that address the genetic mutations responsible. By leveraging its expertise in genomics and precision medicine, Vertex aims to provide effective treatment options for patients with limited or no existing therapeutic options.

What is the P/E ratio of Vertex Pharmaceuticals 2025?

The P/E ratio cannot be calculated for Vertex Pharmaceuticals at the moment.

What is the P/S ratio of Vertex Pharmaceuticals 2025?

The P/S cannot be calculated for Vertex Pharmaceuticals currently.

What is the Quality Investing of Vertex Pharmaceuticals?

The Quality Investing for Vertex Pharmaceuticals is 6/10.

What is the revenue of Vertex Pharmaceuticals 2025?

The expected Vertex Pharmaceuticals revenue is 12.22 B USD.

How high is the profit of Vertex Pharmaceuticals 2025?

The expected Vertex Pharmaceuticals profit is 4.75 B USD.

What is the business model of Vertex Pharmaceuticals

Vertex Pharmaceuticals Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative drugs for the treatment of serious and life-threatening diseases. The company was founded in 1989 and is headquartered in Boston, Massachusetts, USA.

What is the Vertex Pharmaceuticals dividend?

Vertex Pharmaceuticals pays a dividend of 0 USD distributed over payouts per year.

How often does Vertex Pharmaceuticals pay dividends?

The dividend cannot currently be calculated for Vertex Pharmaceuticals or the company does not pay out a dividend.

What is the Vertex Pharmaceuticals ISIN?

The ISIN of Vertex Pharmaceuticals is US92532F1003.

What is the Vertex Pharmaceuticals WKN?

The WKN of Vertex Pharmaceuticals is 882807.

What is the Vertex Pharmaceuticals ticker?

The ticker of Vertex Pharmaceuticals is VRTX.

How much dividend does Vertex Pharmaceuticals pay?

Over the past 12 months, Vertex Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Vertex Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Vertex Pharmaceuticals?

The current dividend yield of Vertex Pharmaceuticals is .

When does Vertex Pharmaceuticals pay dividends?

Vertex Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Vertex Pharmaceuticals?

Vertex Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Vertex Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Vertex Pharmaceuticals located?

Vertex Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Vertex Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Vertex Pharmaceuticals from 9/20/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/20/2025.

When did Vertex Pharmaceuticals pay the last dividend?

The last dividend was paid out on 9/20/2025.

What was the dividend of Vertex Pharmaceuticals in the year 2024?

In the year 2024, Vertex Pharmaceuticals distributed 0 USD as dividends.

In which currency does Vertex Pharmaceuticals pay out the dividend?

The dividends of Vertex Pharmaceuticals are distributed in USD.

All fundamentals about Vertex Pharmaceuticals

Our stock analysis for Vertex Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Vertex Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.